The relationship between oral contraceptive therapy (OCT) and venous thromboembolism (VTE) is a well-established fact (1) (2) (3) (4) (5) (6) . It is commonly believed that women taking OCT have approximately a fourfold increased risk of developing VTE as compared to women of the same age (4) . Patients with congenital prothrombotic conditions such as antithrombin III (ATIII), protein C, or protein S deficiencies are at particular risk of thrombotic complications (7) (8) (9) (10) . Minor congenital prothrombotic conditions such as FV Leiden are also at risk, although to a smaller extent (11) (12) (13) (14) . The role of the G-to-A prothrombin polymorphisms is still controversial (15, 16) . The prescription pattern of oral contraceptives has changed during the past few decades for several reasons. At first, pills containing high doses of ethynilestradiol equal or higher than 0.050 mg were used. Subsequently, in an attempt to reduce side effects, the content of ethynilestradiol was decreased to 0.030 or 0.035 mg and recently even to 0.020 (5) (6) (7) . A few years later it was discovered that the progestative component of the preparations may have had a role in the pathogenesis of venous thrombosis. Furthermore, new progestins were looked for in an attempt to eliminate or reduce their androgenic effects. A few years after the introduction of two new progestins (gestodene and desogestrel), evidence was published indicating that these third-generation progestins were more thrombogenic compared to previous compounds (1, (17) (18) (19) (20) (21) (22) (23) (24) . The conclusions of these studies were criticized and the subject has been strongly debated (25) (26) (27) (28) (29) (30) . The problem is still debated, even though the overall impression of the majority of investigators seem to favor the greater thrombogenic risk of the new progestins (24) . We have investigated the relationship between the number and/or type of prescriptions filled in the Padua province of northeastern Italy during an 11-year period (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) included), and the number of cases of venous thromboembolism seen in Padua during the same time.
MATERIALS AND METHODS
In August and September 2001, a questionnaire was sent to half the total number of pharmacies (112 of 226) located in the territory of the province of Padua. Pharmacies were selected in a blind way, taking only their geographical distribution into consideration. All districts and areas of the province were involved. Such territory comprises an area of approximately 2,200 km2 and is inhabited by approximately 900,000 people. Socioeconomic status is good and representative of an average province of northern Italy. The economic state is based on a florid agriculture, and florid small-or medium-size industries. A large university, a large city hospital, and several secondary and technical schools represent important stimuli for a progressive environment. During the same time, 146 women who resided in the Padua province area were diagnosed with venous thromboembolism while on oral contraceptives either in our outpatient clinic or were admitted in our department of medicine. Women who resided in other provinces of northeastern Italy and who were not seen by us were excluded from the study. In every instance diagnosis was established by objective means (compression ultrasonography and phlebography in doubtful cases). Ventilation/perfusion lung scintiscans and/or spiral computed tomography were performed in approximately 80 of the 146 cases and in all patients with even minimal clinical suspicion of pulmonary embolism. All patients had been taking oral contraceptives for a variable time (1 to 18 cycles) but at the time of onset of signs and symptoms of VTE, all patients were still on the medication.
Patients were classified according to the type of progestin present in the preparation being taken at diagnosis. One group comprised all symptomatic women taking third-generation compounds, namely gestodene and desogestrel, the other group comprised women taking preparations with all other progestins, namely norethisterone, norgestrel, levonorgestrel, and cyproterone. The age range was 16 to 54 years for the first group (third-generation compounds) and 15 to 51 years for the other group. The presence of associated common risk factors, either congenital or acquired, was also noted. These were congenital defects (AT, protein C, protein S deficiencies, FV Leiden, and the G-to-A 20210 prothrombin polymorphisms) and acquired conditions (recent surgery [within 2 months], trauma of the limbs, presence of cast or splints, or bed immobilization from any cause).
Fifty-one questionnaires were returned. Most of them referred to the prescription pattern observed from 1995 to 2000. All contained data pertaining to the years 1999 and 2000. A few (about 25%) contained data concerning all years investigated, namely from 1990 to 2000. Approximately 50% of prescriptions referred to a single blister whereas the remaining 50% referred to preparations containing three blisters. The total number of prescriptions filled during these years in the 51 pharmacies was approximately 740,000. This figure was attained by adding the number of prescriptions as calculated from the questionnaires. Furthermore, an interview with the pharmacists who were unable to supply the precise number of prescriptions filled for some years allowed us to extrapolate and fill the missing years on the basis of the figures available for close years. This was done, once the pharmacists could state, on the basis of his or her own opinion, that no major change had been noted in these years. The final number was then multiplied by four to compensate for the pharmacists who had failed to answer or for those, about half, who were not involved in the study. As a consequence, we could reach at least an indicative figure for the number of prescriptions filled in the entire province during the period investigated, namely 2,960,000 (Fig. 1) .
The ratio between preparations containing third-generation progestins and those containing other progestins varied considerably during the years. It was below or around one for the first few years and then it radically changed in favor of preparations containing third-generation compounds, reaching approximately 80% of total in the last years of the observation period (Fig. 2) . The number of objectively documented episodes of venous thromboembolism (DVT and/or PE) was gathered on a yearly basis. A steady increase was noted from the years 1990, reaching the highest level in 1999 to 2000 (Fig. 3) . There was no significant difference in the presence of associated risk factors in the group taking preparations containing third-generation progestins from the group treated with preparations containing old progestins. This was true for both congenital and acquired risk factors (Table 1) . In every instance, the congenital defect was not known to the prescribing physician. The explosion in the use of preparations containing third-generation compounds occurred in Italy around 1995 to 1996 despite the appearance of the first data on the adverse coagulation effects of these progestins. The first articles suggesting or demonstrating a more pronounced thrombogenic effect of gestoden and desogestrel appeared in late 1995 or early 1996 (17, 20, 26) . It seems that the purported benefits of low androgenicity overwhelmed the eventual risk of a more pronounced thrombogenic effect (5, 6) . The majority of women who took preparations with old progestins actually contained cyproterone. Cyproterone is an anti-androgen compound widely used for the treatment of mild forms of hirsutism and of acne. We decided to include the preparations containing this compound among the first-or second-generation products because it was widely used in Italy in the late 1980s or early 1990s.
Because the population of the Padua province is representative of all the northern Italian provinces, it may be surmised that the trend found here is indicative of the overall conditions present in northern Italy. The large number of the prescriptions of oral contraceptives could be responsible for the increased incidence of observed deep vein thrombosis without any direct implication of the new progestins. It could just be a matter of numbers. Because women on contraceptive therapy have approximately a fourfold risk of developing venous thrombosis with respect to nonusers, it is not surprising that with a more widespread use of OCT, more women became both symptomatic for venous thromboembolism. This seems to be the case because the number of patients diagnosed to have VTE in our center per year increased in approximately the same fashion as the increase in oral contraceptive consumption. Because the large majority of the women during the past few years took third-generation progestins (approximately eight of ten) it is understandable that these compounds may be associated with an increased risk of VTE. There are some limitations to our study. First, it is unlikely that we have seen all women of the province who developed venous thromboembolism. Our center is a reference center for the entire area but it cannot be excluded that some women might have been diagnosed and treated elsewhere. Second, it is likely that women residing in other areas might have used some of the preparations sold in the area we have investigated. However, altogether these limitations do not appear to bias the results of the study. The two limitations may even neutralize themselves. Another important potential limitation of the present study lies in the difficulties encountered in the collection of the information from some of the pharmacies contacted. We have done our best in gathering adequate information, but a word of caution is warranted. Finally, the possibility that more high-risk patients had been treated during the 1990s as compared to the early 1990s can be dismissed. The contrary is probably true because in the late 1990s screening techniques were more widely available.
Our data do not support, even though do not completely exclude, the contention that preparations containing gestodene or desogestrel are associated with an increased risk of venous thromboembolism as compared to preparations containing old progestins. The widespread use of third-generation preparation appears to be here to stay. The fact that these compounds have recently been found to have no influence on the occurrence of myocardial infarction may further confirm this trend (31) . After an initial scare, the approach has been, at least in Italy, more careful. It is probably the responsibility of the prescribing physician to ascertain which preparation is most suited for any given patient (32) . One has always to remember that VTE may be associated with prolonged and important sequellae (postphlebitic syndrome, pulmonary fibrosis, etc.) (33, 34) . Despite the results of this study, the cautious recommendation of the European Agency for the evaluation of medicinal products with regard to the use of third generation progestins should be followed until the problem is finally settled (35) . Women with a positive family history and, particularly, with a positive personal history of idiopathic VTE should not be treated (36) . The need for an extensive laboratory investigation to rule out the presence of at least the major congenital thrombophilic states (AT, protein C and protein S defects) is also indicated. The need of screening for minor thrombophilic conditions such as FV Leiden is still disputed and probably not justified (4). In conclusion it has to be remembered that venous thrombosis, as for other diseases, is mainly an individual process. Epidemiologic studies may allow a general orientation about a risk but no specific information on the individual patient (37) .
